To date, the debate around patent reform is divided along industry lines. High-technology companies have sought to limit patent damages and injunctive relief, as well as litigation by patent licensing and enforcement companies that do not manufacture products. In contrast, biotechnology and pharmaceutical companies have advocated for strong patent protection because such …